Sponsored by
A small, prospective pilot study from researchers at the University of Pennsylvania, including the Musella Foundation's Chief Scientific Advisor Dr. Steven Brem, evaluated machine learning-guided personalized precision radiation therapy (PPRT) in newly diagnosed IDH-wildtype glioblastoma (GBM). Twenty patients were enrolled after gross total resection, with efficacy analyses reported for 17 patients. The PPRT used an AI-based model to estimate patterns of microscopic tumor infiltration beyond what was visible on MRI to personalize radiation targeting, followed by standard temozolomide.
Compared with a matched historical control group, PPRT was associated with improved median progression-free survival (24.4 vs 11.6 months) and overall survival (35.4 vs 17.7 months). Treatment was generally well tolerated, with no grade ≥3 acute toxicities, but radiation necrosis was more frequent in the PPRT group. These findings will need further validation in larger studies, but we hope to see the survival gains replicated.